Top stories from the Proactive Investors UK newsroom.
The much awaited feasibility study on Asiamet’s (LON:ARS) BKM project’s out this morning revealing an initial 9 year mine life producing up to 25,000 tonnes of copper cathode a year. The Post Tax NPV’s come in at $133.5 million.
Faron Pharmaceuticals Oy (LON:FARN) has released the final results of the YODA study into its interferon-beta drug Traumakine. A phase III clinical trial – called “INTEREST” - on patients with a condition called acute respiratory distress syndrome didn’t yield the anticipated results, and the YODA study was instigated to find out why.
Frontier IP Group PLC’s (LON:FIPP) portfolio firm Exscientia has entered a drug discovery collaboration with Shanghai-based biotech GT Apeiron Therapeutics. As part of the partnership Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programme